c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences

The c-Met receptor, also known as the HGF receptor, is one of the most studied tyrosine kinase receptors, yet its biological functions and activation mechanisms are still not fully understood. c-Met has been implicated in embryonic development and organogenesis, in tissue remodelling homeostasis and repair and in cancer metastasis. These functions are indicative of the many cellular processes in which the receptor plays a role, including cell motility, scattering, survival and proliferation. In the context of malignancy, sustained activation of c-Met leads to a signalling cascade involving a multitude of kinases that initiate an invasive and metastatic program. Many proteins can affect the activation of c-Met, including a variety of other cell surface and membrane-spanning molecules or receptors. Some cell surface molecules share structural homology with the c-Met extracellular domain and can activate c-Met via clustering through this domain (e.g., plexins), whereas other receptor tyrosine kinases can enhance c-Met activation and signalling through intracellular signalling cascades (e.g., EGFR). In this review, we provide an overview of c-Met interactions and crosstalk with partner molecules and the functional consequences of these interactions on c-Met activation and downstream signalling, c-Met intracellular localization/recycling and c-Met degradation.

[1]  A. Can,et al.  Reciprocal Activating Crosstalk between c-Met and Caveolin 1 Promotes Invasive Phenotype in Hepatocellular Carcinoma , 2014, PloS one.

[2]  P. Comoglio,et al.  Met-mediated Resistance to Egfr Inhibitors: an Old Liaison Rooted in Colorectal Cancer Stem Cells Egfr Is a Therapeutic Target in Colorectal Cancer Met Activation Is a Mechanism of Resistance to Egfr Inhibition , 2022 .

[3]  D. Parums,et al.  Current status of targeted therapy in non-small cell lung cancer. , 2014, Drugs of today.

[4]  P. Mukherjee,et al.  MUC1: a multifaceted oncoprotein with a key role in cancer progression. , 2014, Trends in molecular medicine.

[5]  J. Ivaska,et al.  Tensin-4-Dependent MET Stabilization Is Essential for Survival and Proliferation in Carcinoma Cells , 2014, Developmental cell.

[6]  T. Stinchcombe Novel agents in development for advanced non-small cell lung cancer , 2014, Therapeutic advances in medical oncology.

[7]  P. Parker,et al.  Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways , 2014, Nature Communications.

[8]  Wanlu Du,et al.  Targeting c-Met Receptor Overcomes TRAIL-Resistance in Brain Tumors , 2014, PloS one.

[9]  R. Jarvis,et al.  Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase , 2014, Journal of Cell Science.

[10]  B. Geiger,et al.  The integrin adhesome: from genes and proteins to human disease , 2014, Nature Reviews Molecular Cell Biology.

[11]  R. Markwald,et al.  Overexpression of c-Met and CD44v6 Receptors Contributes to Autocrine TGF-β1 Signaling in Interstitial Lung Disease* , 2014, The Journal of Biological Chemistry.

[12]  R. Govindan,et al.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Ryan J. Jacobs,et al.  Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer , 2013, PloS one.

[14]  Jianing Zhang,et al.  Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway. , 2013, The international journal of biochemistry & cell biology.

[15]  F. Ciardiello,et al.  Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells , 2013, Clinical Cancer Research.

[16]  D. Nguyen,et al.  EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. , 2013, Cancer research.

[17]  M. Williamson,et al.  Function of mutant and wild-type plexinB1 in prostate cancer cells , 2013, The Prostate.

[18]  G. V. Vande Woude,et al.  Strengthening Context-Dependent Anticancer Effects on Non–Small Cell Lung Carcinoma by Inhibition of Both MET and EGFR , 2013, Molecular Cancer Therapeutics.

[19]  C. Croce,et al.  Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2 , 2013, Proceedings of the National Academy of Sciences.

[20]  Angeliki Mela,et al.  CD82 Blocks cMet Activation and Overcomes Hepatocyte Growth Factor Effects on Oligodendrocyte Precursor Differentiation , 2013, The Journal of Neuroscience.

[21]  M. Kuwano,et al.  Sorting nexin 2‐mediated membrane trafficking of c‐Met contributes to sensitivity of molecular‐targeted drugs , 2013, Cancer science.

[22]  David Koschut,et al.  Internalization of Met Requires the Co-Receptor CD44v6 and Its Link to ERM Proteins , 2013, PloS one.

[23]  Caicun Zhou,et al.  Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer , 2013, Cancer Cell International.

[24]  J. Satagopan,et al.  β4 Integrin signaling induces expansion of prostate tumor progenitors. , 2013, The Journal of clinical investigation.

[25]  J. Soong,et al.  Plexin B1 inhibits MET through direct association and regulates Shp2 expression in melanocytes , 2013, Journal of Cell Science.

[26]  R. Salgia,et al.  Critical Role of S1PR1 and Integrin β4 in HGF/c-Met-mediated Increases in Vascular Integrity , 2012, The Journal of Biological Chemistry.

[27]  Benjamin G. Bitler,et al.  MUC1 Drives c-Met–Dependent Migration and Scattering , 2012, Molecular Cancer Research.

[28]  C. Korch,et al.  Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis , 2012, Molecular Cancer.

[29]  Tianliang Sun,et al.  Grb2 mediates semaphorin-4D-dependent RhoA inactivation , 2012, Journal of Cell Science.

[30]  S. Goodman,et al.  Integrins as therapeutic targets. , 2012, Trends in pharmacological sciences.

[31]  J. Norman,et al.  Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion , 2012, Oncogene.

[32]  L. Cingolani,et al.  Tetraspanins: Interactions and interplay with integrins. , 2012, The international journal of biochemistry & cell biology.

[33]  M. Tremblay,et al.  Protein-tyrosine Phosphatase 1B Modulates Early Endosome Fusion and Trafficking of Met and Epidermal Growth Factor Receptors* , 2011, The Journal of Biological Chemistry.

[34]  J. Heino,et al.  Cooperation between integrins and growth factor receptors in signaling and endocytosis. , 2011, Annual review of cell and developmental biology.

[35]  L. Sequist,et al.  Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  I. Okamoto,et al.  Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification , 2011, British Journal of Cancer.

[37]  G. Pace,et al.  c-Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 in Cd44 null mice , 2011, Molecular biology of the cell.

[38]  V. Calléja,et al.  A direct role for Met endocytosis in tumorigenesis , 2011, Nature Cell Biology.

[39]  Morag Park,et al.  GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. , 2011, Developmental cell.

[40]  Xianghong Jing,et al.  Functional and biochemical studies of CD9 in fibrosarcoma cell line , 2011, Molecular and Cellular Biochemistry.

[41]  Stephen L. Abrams,et al.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.

[42]  A. Dulak,et al.  HGF-independent Potentiation of EGFR Action by c-Met , 2011, Oncogene.

[43]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[44]  E. Lengyel,et al.  Ligand independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis , 2010, Oncogene.

[45]  L. Trusolino,et al.  The Tetraspanin CD151 Is Required for Met-dependent Signaling and Tumor Cell Growth* , 2010, The Journal of Biological Chemistry.

[46]  Atsushi Kumanogoh,et al.  Roles of Sema4D and Plexin-B1 in tumor progression , 2010, Molecular Cancer.

[47]  G. V. Vande Woude,et al.  MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. , 2010, Cancer research.

[48]  L. Leng,et al.  c-Met and Its Ligand Hepatocyte Growth Factor/Scatter Factor Regulate Mature B Cell Survival in a Pathway Induced by CD74 , 2010, The Journal of Immunology.

[49]  H. Kerl,et al.  HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta. , 2010, The Journal of investigative dermatology.

[50]  Morag Park,et al.  Dorsal Ruffle Microdomains Potentiate Met Receptor Tyrosine Kinase Signaling and Down-regulation* , 2010, The Journal of Biological Chemistry.

[51]  M. Williamson,et al.  Plexin B1 suppresses c-Met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-Met. , 2010, The Journal of investigative dermatology.

[52]  R. Markwald,et al.  Stromal Hyaluronan Interaction with Epithelial CD44 Variants Promotes Prostate Cancer Invasiveness by Augmenting Expression and Function of Hepatocyte Growth Factor and Androgen Receptor* , 2010, The Journal of Biological Chemistry.

[53]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[54]  F. Marshall,et al.  Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells , 2010, Molecular Cancer.

[55]  J. Norman,et al.  Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.

[56]  Morag Park,et al.  Crosstalk in Met receptor oncogenesis. , 2009, Trends in cell biology.

[57]  S. Pietronave,et al.  Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene , 2009, Cancer science.

[58]  S. Qin,et al.  Coordinate integrin and c-Met signaling regulate Wnt gene expression during epithelial morphogenesis , 2009, Development.

[59]  K. Nakashiro,et al.  CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. , 2009, Biochemical and biophysical research communications.

[60]  M. Tremblay,et al.  Regulation of the Met Receptor-tyrosine Kinase by the Protein-tyrosine Phosphatase 1B and T-cell Phosphatase* , 2008, Journal of Biological Chemistry.

[61]  Y. Yatabe,et al.  Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.

[62]  N. Rosen,et al.  HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells , 2008, Molecular Cancer Therapeutics.

[63]  Andrew J. Lindsay,et al.  Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments , 2008, The Journal of cell biology.

[64]  P. Singh,et al.  Phosphorylation of MUC1 by Met Modulates Interaction with p53 and MMP1 Expression* , 2008, Journal of Biological Chemistry.

[65]  P. Parker,et al.  Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation , 2008, The Journal of cell biology.

[66]  Deborah S. Barkauskas,et al.  Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer , 2008, British Journal of Cancer.

[67]  I. Shimomura,et al.  The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells , 2008, Journal of cellular physiology.

[68]  S. Ethier,et al.  Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. , 2008, Cancer research.

[69]  M. Zutter,et al.  Crosstalk between the alpha2beta1 integrin and c-met/HGF-R regulates innate immunity. , 2008, Blood.

[70]  K. Carraway,et al.  Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. , 2008, Cancer research.

[71]  S. Offermanns,et al.  ErbB-2 and Met Reciprocally Regulate Cellular Signaling via Plexin-B1* , 2008, Journal of Biological Chemistry.

[72]  Steven P Gygi,et al.  Signaling networks assembled by oncogenic EGFR and c-Met , 2008, Proceedings of the National Academy of Sciences.

[73]  E. Rosen,et al.  Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor , 2008, Molecular Cancer Research.

[74]  Matthias Buck,et al.  Binding of Rac1, Rnd1, and RhoD to a Novel Rho GTPase Interaction Motif Destabilizes Dimerization of the Plexin-B1 Effector Domain* , 2007, Journal of Biological Chemistry.

[75]  K. Shirasuna,et al.  Regulation of c‐Met signaling by the tetraspanin KAI‐1/CD82 affects cancer cell migration , 2007, International journal of cancer.

[76]  R. Salgia,et al.  CD44 Regulates Hepatocyte Growth Factor-mediated Vascular Integrity , 2007, Journal of Biological Chemistry.

[77]  G. Aramuni,et al.  Haploinsufficiency of c-Met in cd44−/− Mice Identifies a Collaboration of CD44 and c-Met In Vivo , 2007, Molecular and Cellular Biology.

[78]  G. Basso,et al.  Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation* , 2007, Journal of Biological Chemistry.

[79]  G. Michalopoulos,et al.  Lack of Fas antagonism by Met in human fatty liver disease , 2007, Nature Medicine.

[80]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[81]  L. Elferink,et al.  Specific Grb2-mediated Interactions Regulate Clathrin-dependent Endocytosis of the cMet-tyrosine Kinase* , 2007, Journal of Biological Chemistry.

[82]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[83]  Ke-Ping Xu,et al.  Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing. , 2007, Investigative ophthalmology & visual science.

[84]  H. Moses,et al.  Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells , 2007, Cancer biology & therapy.

[85]  K. Handa,et al.  Ganglioside GM2-Tetraspanin CD82 Complex Inhibits Met and Its Cross-talk with Integrins, Providing a Basis for Control of Cell Motility through Glycosynapse* , 2007, Journal of Biological Chemistry.

[86]  Y. Fukami,et al.  Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells , 2006, Journal of Cell Science.

[87]  P. Herrlich,et al.  Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. , 2006, Molecular biology of the cell.

[88]  Lee M Ellis,et al.  Regulatory role of c-Met in insulin-like growth factor-I receptor–mediated migration and invasion of human pancreatic carcinoma cells , 2006, Molecular Cancer Therapeutics.

[89]  G. Christofori New signals from the invasive front , 2006, Nature.

[90]  C. Miranti,et al.  Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases , 2006, Oncogene.

[91]  Toshikazu Nakamura,et al.  Contact Inhibition of Hepatocyte Growth Regulated by Functional Association of the c-Met/Hepatocyte Growth Factor Receptor and LAR Protein-tyrosine Phosphatase* , 2006, Journal of Biological Chemistry.

[92]  Shu-yi Chen,et al.  Crosstalk between hepatocyte growth factor and integrin signaling pathways. , 2006, Journal of biomedical science.

[93]  L. Trusolino,et al.  Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. , 2005, Cancer research.

[94]  K. Nakashiro,et al.  CD151 forms a functional complex with c-Met in human salivary gland cancer cells. , 2005, Biochemical and biophysical research communications.

[95]  H. Brady,et al.  cMet and Fas Receptor Interaction Inhibits Death-Inducing Signaling Complex Formation in Endothelial Cells , 2005, Hypertension.

[96]  P. Comoglio,et al.  Sema4D induces angiogenesis through Met recruitment by Plexin B1. , 2005, Blood.

[97]  J. Salles,et al.  A Novel Role for Gab1 and SHP2 in Epidermal Growth Factor-induced Ras Activation* , 2005, Journal of Biological Chemistry.

[98]  P. Parker,et al.  PKC controls HGF‐dependent c‐Met traffic, signalling and cell migration , 2004, The EMBO journal.

[99]  Motonao Nakamura,et al.  MUC20 Suppresses the Hepatocyte Growth Factor-Induced Grb2-Ras Pathway by Binding to a Multifunctional Docking Site of Met , 2004, Molecular and Cellular Biology.

[100]  L. Pelkmans,et al.  Not just a sink: endosomes in control of signal transduction. , 2004, Current opinion in cell biology.

[101]  A. Mercurio,et al.  The Met Receptor and α6β4 Integrin Can Function Independently to Promote Carcinoma Invasion* , 2004, Journal of Biological Chemistry.

[102]  P. Comoglio,et al.  Interplay between scatter factor receptors and B plexins controls invasive growth , 2004, Oncogene.

[103]  Giorgio F. Gilestro,et al.  Plexin‐B3 is a functional receptor for semaphorin 5A , 2004, EMBO reports.

[104]  Christian Wiesmann,et al.  Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor , 2004, The EMBO journal.

[105]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[106]  G. V. Vande Woude,et al.  Endosomal dynamics of Met determine signaling output. , 2003, Molecular biology of the cell.

[107]  N. Tonks,et al.  Hepatocyte Growth Factor Receptor Tyrosine Kinase Met Is a Substrate of the Receptor Protein-tyrosine Phosphatase DEP-1* , 2003, The Journal of Biological Chemistry.

[108]  J. Sleeman,et al.  CD44 is required for two consecutive steps in HGF/c-Met signaling. , 2002, Genes & development.

[109]  Giorgio F. Gilestro,et al.  The Semaphorin 4D receptor controls invasive growth by coupling with Met , 2002, Nature Cell Biology.

[110]  B. Vandenbunder,et al.  Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway , 2002, Oncogene.

[111]  L. Trusolino,et al.  Scatter-factor and semaphorin receptors: cell signalling for invasive growth , 2002, Nature Reviews Cancer.

[112]  Giorgio F. Gilestro,et al.  The endophilin–CIN85–Cbl complex mediates ligand-dependent downregulation of c-Met , 2002, Nature.

[113]  A. Bell,et al.  A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. , 2002, Molecular cell.

[114]  R. Jove,et al.  Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis , 2002, Oncogene.

[115]  L. Trusolino,et al.  A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth , 2001, Cell.

[116]  E. Rosen,et al.  The Multisubstrate Adapter Gab1 Regulates Hepatocyte Growth Factor (Scatter Factor)–c-Met Signaling for Cell Survival and DNA Repair , 2001, Molecular and Cellular Biology.

[117]  G. Woude,et al.  Down-regulation of MET, the receptor for hepatocyte growth factor , 2001, Oncogene.

[118]  Hailan Hu,et al.  Plexin-B semaphorin receptors interact directly with active Rac and regulate the actin cytoskeleton by activating Rho , 2001, Current Biology.

[119]  G. V. Vande Woude,et al.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[120]  D. Kamikura,et al.  A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein , 2000, Oncogene.

[121]  D. Robinson,et al.  The protein tyrosine kinase family of the human genome , 2000, Oncogene.

[122]  C. Maroun,et al.  The Tyrosine Phosphatase SHP-2 Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase , 2000, Molecular and Cellular Biology.

[123]  M. Naujokas,et al.  Identification of an Atypical Grb2 Carboxyl-terminal SH3 Domain Binding Site in Gab Docking Proteins Reveals Grb2-dependent and -independent Recruitment of Gab1 to Receptor Tyrosine Kinases* , 2000, The Journal of Biological Chemistry.

[124]  W. Birchmeier,et al.  Essential Role of Gab1 for Signaling by the C-Met Receptor in Vivo , 2000, The Journal of cell biology.

[125]  W. Birchmeier,et al.  Coupling of Gab1 to C-Met, Grb2, and Shp2 Mediates Biological Responses , 2000, The Journal of cell biology.

[126]  M. Stella,et al.  Cross-talk between the proto-oncogenes Met and Ron , 2000, Oncogene.

[127]  D. Stolz,et al.  Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells* , 2000, The Journal of Biological Chemistry.

[128]  P. Comoglio,et al.  Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis , 2000, Oncogene.

[129]  K. Vuori,et al.  Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 – Crk signaling complex formation , 1999, Oncogene.

[130]  L. Buday,et al.  Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. , 1999, Cellular signalling.

[131]  M. Poo,et al.  Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates , 1999, Cell.

[132]  E. Gherardi,et al.  Heparan Sulfate-modified CD44 Promotes Hepatocyte Growth Factor/Scatter Factor-induced Signal Transduction through the Receptor Tyrosine Kinase c-Met* , 1999, The Journal of Biological Chemistry.

[133]  Morag Park,et al.  The Gab1 PH Domain Is Required for Localization of Gab1 at Sites of Cell-Cell Contact and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase , 1999, Molecular and Cellular Biology.

[134]  J. Downward,et al.  Phosphoinositide 3-Kinase Induces Scattering and Tubulogenesis in Epithelial Cells through a Novel Pathway* , 1998, The Journal of Biological Chemistry.

[135]  A. Bardelli,et al.  Induction of epithelial tubules by growth factor HGF depends on the STAT pathway , 1998, Nature.

[136]  Alexis Gautreau,et al.  Ezrin Is an Effector of Hepatocyte Growth Factor–mediated Migration and Morphogenesis in Epithelial Cells , 1997, The Journal of cell biology.

[137]  S. Ōmura,et al.  Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway , 1997, Molecular and cellular biology.

[138]  W. Birchmeier,et al.  Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis , 1996, Nature.

[139]  J. Bishop,et al.  Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[140]  M. Glimcher,et al.  Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1) , 1996, Science.

[141]  A. Bardelli,et al.  The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. , 1995, Oncogene.

[142]  K.,et al.  The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. , 1994, The Journal of biological chemistry.

[143]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.

[144]  J. Mendelsohn,et al.  Consumption of EGF by A431 cells: evidence for receptor recycling , 1993, The Journal of cell biology.

[145]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[146]  C. Cooper,et al.  Tyrosine kinase receptor indistinguishable from the c-met protein , 1989, Nature.

[147]  M. Braun,et al.  Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[148]  Michael Stoker,et al.  Scatter factor is a fibroblast-derived modulator of epithelial cell mobility , 1987, Nature.

[149]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[150]  T. Pellinen,et al.  Negative regulation of EGFR signalling through integrin-alpha1beta1-mediated activation of protein tyrosine phosphatase TCPTP. , 2005, Nature cell biology.

[151]  Jacqueline Murray,et al.  Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. , 2005, BMC Cell Biology.

[152]  L. Trusolino,et al.  A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. , 2001, Cell.

[153]  L. Vician,et al.  The Urokinase Plasminogen Activator Receptor (UPAR) Is Preferentially Induced by Nerve Growth Factor in PC12 Pheochromocytoma Cells and Is Required for NGF-Driven Differentiation , 2000, Journal of Neuroscience.

[154]  P. P. Di Fiore,et al.  Endocytosis and mitogenic signaling. , 1999, Current opinion in cell biology.